Hassan, R. (2017). Genome Editing and Chimeric Antigen Receptors T Cell Therapy. Suez Canal University Medical Journal, 20(2), 122-127. doi: 10.21608/scumj.2017.43560
Ranya Hassan. "Genome Editing and Chimeric Antigen Receptors T Cell Therapy". Suez Canal University Medical Journal, 20, 2, 2017, 122-127. doi: 10.21608/scumj.2017.43560
Hassan, R. (2017). 'Genome Editing and Chimeric Antigen Receptors T Cell Therapy', Suez Canal University Medical Journal, 20(2), pp. 122-127. doi: 10.21608/scumj.2017.43560
Hassan, R. Genome Editing and Chimeric Antigen Receptors T Cell Therapy. Suez Canal University Medical Journal, 2017; 20(2): 122-127. doi: 10.21608/scumj.2017.43560
Genome Editing and Chimeric Antigen Receptors T Cell Therapy
Clinical pathology Department, Faculty of Medicine, Suez Canal university, Egypt
Abstract
Recent advances in genome editing technologies have significantly enhanced making specific changes in the genomes of different types cells. Genetically engineered T cells, or the 'living drugs', is considered a new era in antitumor therapy. Current clinical trials using chimeric antigen receptors (CARs) T cells showed a promising result in patients with some intractable hematological malignancies. In this Review, some of the most recent advances in CAR T cell therapy are mentioned high lightening the use of genome editing in this field.
View on SCiNiTO
Top